Kainos Medicine, Inc. (KOSDAQ:284620)

Kainos Medicine Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	4,222	3,834	16,337	24,952	23,231	21,952
Short-Term Investments	-	-	79.85	5,000	11,000	6,000
Trading Asset Securities	-	-	-	-	-	1,860
Cash & Short-Term Investments	4,222	3,834	16,417	29,952	34,231	29,812
Cash Growth	-48.35%	-76.64%	-45.19%	-12.50%	14.82%	682.29%
Accounts Receivable	278.11	252.77	83.75	-0	0	-0
Other Receivables	71.19	62.53	4.35	295.7	290.89	59.02
Receivables	349.29	490.3	88.1	295.7	290.89	59.02
Prepaid Expenses	74.88	96.69	258.68	949.3	2,020	197.25
Other Current Assets	317.01	182.94	353.43	38.45	331.12	1,918
Total Current Assets	5,645	4,604	17,117	31,236	36,873	31,987
Property, Plant & Equipment	285.08	602.75	875.47	5,437	3,334	1,851
Long-Term Investments	1,940	3,503	786.56	740.63	642.79	-
Other Intangible Assets	442.41	501.61	810.67	861.84	689.04	481.59
Long-Term Accounts Receivable	0	-0	0	-0	-0	0
Other Long-Term Assets	1,439	1,531	1,395	707.04	418.79	458.9
Total Assets	9,751	10,742	20,985	38,982	41,957	34,779
Accrued Expenses	124.54	99.83	49.92	65.04	575.51	197.4
Short-Term Debt	-	-	-	761.67	12,468	-
Current Portion of Long-Term Debt	-	-	-	2,285	-	-
Current Portion of Leases	225.96	355.37	352.17	550.74	276.27	269.75
Other Current Liabilities	1,531	1,931	1,400	1,213	8,779	436.18
Total Current Liabilities	1,881	2,386	1,802	4,876	22,099	903.33
Long-Term Debt	-	-	-	-	1,523	10,739
Long-Term Leases	-	135.91	48.66	314.34	103.95	284.97
Other Long-Term Liabilities	35.15	33.75	36.62	73.8	73.92	6,567
Total Liabilities	1,916	2,556	1,888	5,264	23,800	18,494
Common Stock	16,543	14,090	13,961	13,961	11,029	10,494
Additional Paid-In Capital	116,022	111,617	110,117	110,117	84,564	71,602
Retained Earnings	-134,533	-128,605	-116,414	-101,179	-85,298	-69,087
Treasury Stock	-40.95	-40.95	-55.12	-55.12	-22.72	-22.72
Comprehensive Income & Other	4,182	4,726	4,143	3,266	1,831	-634.39
Total Common Equity	2,173	1,788	11,751	26,109	12,104	12,353
Minority Interest	3,456	4,086	4,020	3,808	2,497	667.81
Shareholders' Equity	7,835	8,186	19,098	33,719	18,157	16,284
Total Liabilities & Equity	9,751	10,742	20,985	38,982	41,957	34,779
Total Debt	225.96	491.29	400.83	3,912	14,372	11,294
Net Cash (Debt)	3,996	3,343	16,016	26,040	19,859	18,519
Net Cash Growth	-47.73%	-79.13%	-38.50%	31.12%	7.24%	413.89%
Net Cash Per Share	131.68	120.05	573.59	1092.41	937.14	913.99
Filing Date Shares Outstanding	31.25	27.81	27.92	27.92	22.06	20.99
Total Common Shares Outstanding	31.25	27.81	27.92	27.92	22.06	20.99
Working Capital	3,764	2,218	15,315	26,360	14,774	31,083
Book Value Per Share	69.55	64.30	420.94	935.25	548.77	588.61
Tangible Book Value	1,731	1,286	10,941	25,247	11,414	11,871
Tangible Book Value Per Share	55.39	46.26	391.90	904.38	517.53	565.66
Machinery	739.46	743.51	760.19	749.6	725.66	1,061
Construction In Progress	-	-	-	3,829	2,287	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.